GH Research PLC (NASDAQ: GHRS) reported a net loss of $48.3 million, or $0.79 per share, for the year ended December 31 2025, with no product sales recorded. Cash, cash equivalents and marketable securities rose to $280.7 million, up from $182.6 million at the end of 2024, giving the company a strong liquidity position to fund future clinical milestones. Research and development expenses increased to $38.8 million, while general and administrative costs grew to $22.0 million, reflecting expanded technical development, non‑clinical activities, employee expenses and professional fees.
The year‑over‑year comparison shows the net loss widened from $39.0 million in 2024, driven primarily by the higher R&D and G&A outlays. The increase in R&D spending was largely due to intensified technical development and non‑clinical work, while the rise in G&A was attributable to higher professional fees and employee costs. Despite the loss, the company’s cash runway has expanded by nearly $100 million, underscoring its capacity to support the next phase of development.
In its business update, GH Research highlighted the completion of a Phase 2b trial of GH001 for treatment‑resistant depression, with the full dataset presented at the 2025 American Society of Clinical Psychopharmacology and European College of Neuropsychopharmacology meetings. The company is actively seeking FDA alignment on the design of its global Phase 3 pivotal program, which it aims to launch in 2026. Additionally, the proprietary aerosol delivery device completed a Phase 1 clinical pharmacology trial in healthy volunteers and will be incorporated into the upcoming pivotal program.
Chief Executive Officer Dr. Velichka Valcheva said, “The FDA clearance is a major milestone and positions us to advance GH001 as a potential ultra‑rapid and durable treatment option for TRD patients.” She added, “We continue to expect initiation of our global pivotal program in 2026 and look forward to meeting with the FDA to align on the design for the pivotal Phase 3 program.” Valcheva also noted that “Our Phase 2b results reinforce our conviction that GH001 has the potential to be a practice‑changing therapy for patients with TRD.”
The company’s focus on its 5‑MeO‑DMT platform, combined with the successful Phase 2b data and the FDA’s lifting of the clinical hold, de‑risks the pipeline and positions GH Research to pursue a practice‑changing therapy for treatment‑resistant depression, bipolar II disorder and postpartum depression. The robust cash position and the planned use of the aerosol device in the pivotal program provide a clear path toward regulatory approval and eventual commercialization. The single‑segment structure—Research and Development—highlights the company’s status as a clinical‑stage biopharmaceutical firm, where revenue is not yet generated and losses are expected as the company invests in advancing its pipeline.
The financial results and business update reinforce GH Research’s trajectory toward a Phase 3 program in 2026, while maintaining a strong liquidity base to support the next milestones in its 5‑MeO‑DMT platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.